Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Everest Medicines Announces First Patient Dosed In A Phase 1b 2 Study Of Fgf401 In Combination With Pembrolizumab For The Treatment Of Advanced Solid Tumors is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
today announced that the first patient has been dosed in its Phase 1/2a trial of IMM-6-415 to treat advanced solid tumors with RAF or RAS mutations. IMM-6-415 is a Deep Cyclic Inhibitor (DCI ... Read More
Alyssum Therapeutics Announces First Patient Dosed in Phase 1/2 Study of AT-1965, a CMTR2 Inhibitor, in Solid Tumors
CAMBRIDGE, MA, USA, April 10, 2024 /EINPresswire.com/ -- Alyssum Therapeutics, a biotechnology company which is developing next-generation immunotherapies to modulate ... Read More
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
SAN DIEGO, April 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to evaluate the ... Read More
ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa
today announced that the first patient has been dosed in its Phase Ib clinical trial evaluating intravitreal injection of VG901 to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 ... Read More
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
and chronic inducible urticaria (CIndU), today announced that the first patient has been dosed in Jasper’s Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of ... Read More
Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients
The NefIgArd study is a 2-year trial, which consisted of nine months of treatment ... of this news release, except as required by law. SparX Group Announces First Patient Dosed with SPX-303 ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus